donor	alteration_class	oncokb_level	indication	treatment	gene	alteration_type
BTC0015	V600	3.5	Erdheim-Chester Disease	Vemurafenib	BRAF	V600E
BTC0015	V600	3.5	Melanoma	Vemurafenib + Atezolizumab + Cobimetinib	BRAF	V600E
BTC0015	V600E	1	All Solid Tumors (excluding Colorectal Cancer)	Dabrafenib + Trametinib	BRAF	V600E
BTC0015	V600E	3.5	Anaplastic Thyroid Cancer	Dabrafenib + Trametinib	BRAF	V600E
BTC0015	V600E	1	Biliary Tract Cancer, NOS	Dabrafenib + Trametinib	BRAF	V600E
BTC0015	V600E	3.5	Colorectal Cancer	Encorafenib + Cetuximab	BRAF	V600E
BTC0015	V600E	3.5	Melanoma	Dabrafenib	BRAF	V600E
BTC0015	V600E	3.5	Melanoma	Vemurafenib	BRAF	V600E
BTC0015	V600E	3.5	Non-Small Cell Lung Cancer	Dabrafenib + Trametinib	BRAF	V600E
BTC0015	V600E	3.5	Non-Small Cell Lung Cancer	Encorafenib + Binimetinib	BRAF	V600E
BTC0015	V600E	3.5	Melanoma	Dabrafenib + Trametinib	BRAF	V600E
BTC0015	V600E	3.5	Melanoma	Encorafenib + Binimetinib	BRAF	V600E
BTC0015	V600E	3.5	Melanoma	Trametinib	BRAF	V600E
BTC0015	V600E	3.5	Melanoma	Vemurafenib + Cobimetinib	BRAF	V600E
BTC0024	Amplification	3.5	Breast Cancer	Ado-Trastuzumab Emtansine	ERBB2	strong amplification
BTC0033	Amplification	3.5	Breast Cancer	Ado-Trastuzumab Emtansine	ERBB2	strong amplification
BTC0038	Amplification	3.5	Breast Cancer	Ado-Trastuzumab Emtansine	ERBB2	FISH
BTC0024	Amplification	3.5	Breast Cancer	Lapatinib + Capecitabine, Lapatinib + Letrozole	ERBB2	strong amplification
BTC0033	Amplification	3.5	Breast Cancer	Lapatinib + Capecitabine, Lapatinib + Letrozole	ERBB2	strong amplification
BTC0038	Amplification	3.5	Breast Cancer	Lapatinib + Capecitabine, Lapatinib + Letrozole	ERBB2	FISH
BTC0024	Amplification	3.5	Breast Cancer	Margetuximab + Chemotherapy	ERBB2	strong amplification
BTC0033	Amplification	3.5	Breast Cancer	Margetuximab + Chemotherapy	ERBB2	strong amplification
BTC0038	Amplification	3.5	Breast Cancer	Margetuximab + Chemotherapy	ERBB2	FISH
BTC0024	Amplification	3.5	Breast Cancer	Neratinib, Neratinib + Capecitabine	ERBB2	strong amplification
BTC0033	Amplification	3.5	Breast Cancer	Neratinib, Neratinib + Capecitabine	ERBB2	strong amplification
BTC0038	Amplification	3.5	Breast Cancer	Neratinib, Neratinib + Capecitabine	ERBB2	FISH
BTC0024	Amplification	3.5	Breast Cancer	Trastuzumab + Pertuzumab + Chemotherapy	ERBB2	strong amplification
BTC0033	Amplification	3.5	Breast Cancer	Trastuzumab + Pertuzumab + Chemotherapy	ERBB2	strong amplification
BTC0038	Amplification	3.5	Breast Cancer	Trastuzumab + Pertuzumab + Chemotherapy	ERBB2	FISH
BTC0024	Amplification	3.5	Breast Cancer	Trastuzumab + Tucatinib + Capecitabine	ERBB2	strong amplification
BTC0033	Amplification	3.5	Breast Cancer	Trastuzumab + Tucatinib + Capecitabine	ERBB2	strong amplification
BTC0038	Amplification	3.5	Breast Cancer	Trastuzumab + Tucatinib + Capecitabine	ERBB2	FISH
BTC0024	Amplification	3.5	Breast Cancer	Trastuzumab Deruxtecan	ERBB2	strong amplification
BTC0033	Amplification	3.5	Breast Cancer	Trastuzumab Deruxtecan	ERBB2	strong amplification
BTC0038	Amplification	3.5	Breast Cancer	Trastuzumab Deruxtecan	ERBB2	FISH
BTC0024	Amplification	3.5	Breast Cancer	Trastuzumab, Trastuzumab + Chemotherapy	ERBB2	strong amplification
BTC0033	Amplification	3.5	Breast Cancer	Trastuzumab, Trastuzumab + Chemotherapy	ERBB2	strong amplification
BTC0038	Amplification	3.5	Breast Cancer	Trastuzumab, Trastuzumab + Chemotherapy	ERBB2	FISH
BTC0024	Amplification	3.5	Colorectal Cancer	Tucatinib + Trastuzumab	ERBB2	strong amplification
BTC0033	Amplification	3.5	Colorectal Cancer	Tucatinib + Trastuzumab	ERBB2	strong amplification
BTC0038	Amplification	3.5	Colorectal Cancer	Tucatinib + Trastuzumab	ERBB2	FISH
BTC0024	Amplification	3.5	Esophagogastric Cancer	Pembrolizumab + Trastuzumab + Chemotherapy	ERBB2	strong amplification
BTC0033	Amplification	3.5	Esophagogastric Cancer	Pembrolizumab + Trastuzumab + Chemotherapy	ERBB2	strong amplification
BTC0038	Amplification	3.5	Esophagogastric Cancer	Pembrolizumab + Trastuzumab + Chemotherapy	ERBB2	FISH
BTC0024	Amplification	3.5	Esophagogastric Cancer	Trastuzumab + Chemotherapy	ERBB2	strong amplification
BTC0033	Amplification	3.5	Esophagogastric Cancer	Trastuzumab + Chemotherapy	ERBB2	strong amplification
BTC0038	Amplification	3.5	Esophagogastric Cancer	Trastuzumab + Chemotherapy	ERBB2	FISH
BTC0024	Amplification	3.5	Esophagogastric Cancer	Trastuzumab Deruxtecan	ERBB2	strong amplification
BTC0033	Amplification	3.5	Esophagogastric Cancer	Trastuzumab Deruxtecan	ERBB2	strong amplification
BTC0038	Amplification	3.5	Esophagogastric Cancer	Trastuzumab Deruxtecan	ERBB2	FISH
BTC0010	Fusions	1	Cholangiocarcinoma	Futibatinib	FGFR2	FGFR2
BTC0018	Fusions	1	Cholangiocarcinoma	Futibatinib	FGFR2	FGFR2
BTC0026	Fusions	1	Cholangiocarcinoma	Futibatinib	FGFR2	FGFR2
BTC0070	Fusions	1	Cholangiocarcinoma	Futibatinib	FGFR2	FGFR2
BTC0010	Fusions	1	Cholangiocarcinoma	Pemigatinib	FGFR2	FGFR2
BTC0018	Fusions	1	Cholangiocarcinoma	Pemigatinib	FGFR2	FGFR2
BTC0026	Fusions	1	Cholangiocarcinoma	Pemigatinib	FGFR2	FGFR2
BTC0070	Fusions	1	Cholangiocarcinoma	Pemigatinib	FGFR2	FGFR2
BTC0018	R132	1	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib	IDH1	R132H
BTC0018	R132	1	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib	IDH1	R132H
BTC0018	R132	1	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib	IDH1	R132H
BTC0028	R132	1	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib	IDH1	R132C
BTC0028	R132	1	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib	IDH1	R132C
BTC0028	R132	1	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib	IDH1	R132C
BTC0028	R132	1	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib	IDH1	R132C
BTC0028	R132	1	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib	IDH1	R132C
BTC0028	R132	1	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib	IDH1	R132C
BTC0042	R132	1	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib	IDH1	R132C
BTC0042	R132	1	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib	IDH1	R132C
BTC0042	R132	1	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib	IDH1	R132C
BTC0054	R132	1	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib	IDH1	R132C
BTC0054	R132	1	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib	IDH1	R132C
BTC0054	R132	1	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib	IDH1	R132C
BTC0064	R132	1	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib	IDH1	R132H
BTC0064	R132	1	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib	IDH1	R132H
BTC0064	R132	1	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib	IDH1	R132H
BTC0028	R132C	3.5	Acute Myeloid Leukemia	Ivosidenib	IDH1	R132C
BTC0028	R132C	3.5	Acute Myeloid Leukemia	Ivosidenib	IDH1	R132C
BTC0028	R132C	3.5	Acute Myeloid Leukemia	Ivosidenib	IDH1	R132C
BTC0028	R132C	3.5	Acute Myeloid Leukemia	Ivosidenib	IDH1	R132C
BTC0028	R132C	3.5	Acute Myeloid Leukemia	Ivosidenib	IDH1	R132C
BTC0028	R132C	3.5	Acute Myeloid Leukemia	Ivosidenib	IDH1	R132C
BTC0042	R132C	3.5	Acute Myeloid Leukemia	Ivosidenib	IDH1	R132C
BTC0042	R132C	3.5	Acute Myeloid Leukemia	Ivosidenib	IDH1	R132C
BTC0042	R132C	3.5	Acute Myeloid Leukemia	Ivosidenib	IDH1	R132C
BTC0054	R132C	3.5	Acute Myeloid Leukemia	Ivosidenib	IDH1	R132C
BTC0054	R132C	3.5	Acute Myeloid Leukemia	Ivosidenib	IDH1	R132C
BTC0054	R132C	3.5	Acute Myeloid Leukemia	Ivosidenib	IDH1	R132C
BTC0018	R132H	3.5	Acute Myeloid Leukemia	Ivosidenib	IDH1	R132H
BTC0018	R132H	3.5	Acute Myeloid Leukemia	Ivosidenib	IDH1	R132H
BTC0018	R132H	3.5	Acute Myeloid Leukemia	Ivosidenib	IDH1	R132H
BTC0064	R132H	3.5	Acute Myeloid Leukemia	Ivosidenib	IDH1	R132H
BTC0064	R132H	3.5	Acute Myeloid Leukemia	Ivosidenib	IDH1	R132H
BTC0064	R132H	3.5	Acute Myeloid Leukemia	Ivosidenib	IDH1	R132H
BTC0028	R132C	3.5	Acute Myeloid Leukemia	Olutasidenib	IDH1	R132C
BTC0028	R132C	3.5	Acute Myeloid Leukemia	Olutasidenib	IDH1	R132C
BTC0028	R132C	3.5	Acute Myeloid Leukemia	Olutasidenib	IDH1	R132C
BTC0028	R132C	3.5	Acute Myeloid Leukemia	Olutasidenib	IDH1	R132C
BTC0028	R132C	3.5	Acute Myeloid Leukemia	Olutasidenib	IDH1	R132C
BTC0028	R132C	3.5	Acute Myeloid Leukemia	Olutasidenib	IDH1	R132C
BTC0042	R132C	3.5	Acute Myeloid Leukemia	Olutasidenib	IDH1	R132C
BTC0042	R132C	3.5	Acute Myeloid Leukemia	Olutasidenib	IDH1	R132C
BTC0042	R132C	3.5	Acute Myeloid Leukemia	Olutasidenib	IDH1	R132C
BTC0054	R132C	3.5	Acute Myeloid Leukemia	Olutasidenib	IDH1	R132C
BTC0054	R132C	3.5	Acute Myeloid Leukemia	Olutasidenib	IDH1	R132C
BTC0054	R132C	3.5	Acute Myeloid Leukemia	Olutasidenib	IDH1	R132C
BTC0018	R132H	3.5	Acute Myeloid Leukemia	Olutasidenib	IDH1	R132H
BTC0018	R132H	3.5	Acute Myeloid Leukemia	Olutasidenib	IDH1	R132H
BTC0018	R132H	3.5	Acute Myeloid Leukemia	Olutasidenib	IDH1	R132H
BTC0064	R132H	3.5	Acute Myeloid Leukemia	Olutasidenib	IDH1	R132H
BTC0064	R132H	3.5	Acute Myeloid Leukemia	Olutasidenib	IDH1	R132H
BTC0064	R132H	3.5	Acute Myeloid Leukemia	Olutasidenib	IDH1	R132H
BTC0028	R132C	3.5	Myelodysplastic Syndromes	Ivosidenib	IDH1	R132C
BTC0028	R132C	3.5	Myelodysplastic Syndromes	Ivosidenib	IDH1	R132C
BTC0028	R132C	3.5	Myelodysplastic Syndromes	Ivosidenib	IDH1	R132C
BTC0028	R132C	3.5	Myelodysplastic Syndromes	Ivosidenib	IDH1	R132C
BTC0028	R132C	3.5	Myelodysplastic Syndromes	Ivosidenib	IDH1	R132C
BTC0028	R132C	3.5	Myelodysplastic Syndromes	Ivosidenib	IDH1	R132C
BTC0042	R132C	3.5	Myelodysplastic Syndromes	Ivosidenib	IDH1	R132C
BTC0042	R132C	3.5	Myelodysplastic Syndromes	Ivosidenib	IDH1	R132C
BTC0042	R132C	3.5	Myelodysplastic Syndromes	Ivosidenib	IDH1	R132C
BTC0054	R132C	3.5	Myelodysplastic Syndromes	Ivosidenib	IDH1	R132C
BTC0054	R132C	3.5	Myelodysplastic Syndromes	Ivosidenib	IDH1	R132C
BTC0054	R132C	3.5	Myelodysplastic Syndromes	Ivosidenib	IDH1	R132C
BTC0018	R132H	3.5	Myelodysplastic Syndromes	Ivosidenib	IDH1	R132H
BTC0018	R132H	3.5	Myelodysplastic Syndromes	Ivosidenib	IDH1	R132H
BTC0018	R132H	3.5	Myelodysplastic Syndromes	Ivosidenib	IDH1	R132H
BTC0064	R132H	3.5	Myelodysplastic Syndromes	Ivosidenib	IDH1	R132H
BTC0064	R132H	3.5	Myelodysplastic Syndromes	Ivosidenib	IDH1	R132H
BTC0064	R132H	3.5	Myelodysplastic Syndromes	Ivosidenib	IDH1	R132H
BTC0013	MSI-H	1	All Solid Tumors	Pembrolizumab	MSI	MSI
BTC0045	MSI-H	1	All Solid Tumors	Pembrolizumab	MSI	MSI
BTC0013	MSI-H	3.5	Colorectal Cancer	Ipilimumab + Nivolumab	MSI	MSI
BTC0045	MSI-H	3.5	Colorectal Cancer	Ipilimumab + Nivolumab	MSI	MSI
BTC0013	MSI-H	3.5	Colorectal Cancer	Nivolumab	MSI	MSI
BTC0045	MSI-H	3.5	Colorectal Cancer	Nivolumab	MSI	MSI
BTC0013	MSI-H	3.5	Endometrial Cancer	Dostarlimab + Carboplatin + Paclitaxel	MSI	MSI
BTC0045	MSI-H	3.5	Endometrial Cancer	Dostarlimab + Carboplatin + Paclitaxel	MSI	MSI
BTC0013	TMB-H	1	All Solid Tumors	Pembrolizumab	TMB	TMB
BTC0014	TMB-H	1	All Solid Tumors	Pembrolizumab	TMB	TMB
BTC0025	TMB-H	1	All Solid Tumors	Pembrolizumab	TMB	TMB
BTC0045	TMB-H	1	All Solid Tumors	Pembrolizumab	TMB	TMB
BTC0064	E542K	3.5	Breast Cancer	Alpelisib + Fulvestrant	PIK3CA	E542K
BTC0027	E545K	3.5	Breast Cancer	Alpelisib + Fulvestrant	PIK3CA	E545K
BTC0013	H1047R	3.5	Breast Cancer	Alpelisib + Fulvestrant	PIK3CA	H1047R
BTC0013	H1047R	3.5	Breast Cancer	Capivasertib + Fulvestrant	PIK3CA	H1047R
BTC0027	E545K	3.5	Breast Cancer	Capivasertib + Fulvestrant	PIK3CA	E545K
BTC0064	E542K	3.5	Breast Cancer	Capivasertib + Fulvestrant	PIK3CA	E542K
BTC0016	Oncogenic Mutations	3.5	Breast Cancer	Capivasertib + Fulvestrant	PTEN	homozygous deletion
BTC0052	Oncogenic Mutations	3.5	Breast Cancer	Capivasertib + Fulvestrant	PTEN	homozygous deletion
BTC0080	Oncogenic Mutations	3.5	Breast Cancer	Capivasertib + Fulvestrant	PTEN	homozygous deletion
BTC0015	V600	3.5	Langerhans Cell Histiocytosis	Vemurafenib, Dabrafenib	BRAF	V600E
BTC0015	V600E	3.5	Colorectal Cancer	Encorafenib + Panitumumab	BRAF	V600E
BTC0015	V600E	3.5	Diffuse Glioma	Vemurafenib + Cobimetinib	BRAF	V600E
BTC0015	V600E	3.5	Encapsulated Glioma	Vemurafenib + Cobimetinib	BRAF	V600E
BTC0015	V600E	3.5	Hairy Cell Leukemia	Vemurafenib	BRAF	V600E
BTC0015	V600E	3.5	Pilocytic Astrocytoma	Selumetinib	BRAF	V600E
BTC0015	V600E	3.5	Pleomorphic Xanthoastrocytoma, Pilocytic Astrocytoma, Ganglioglioma	Vemurafenib + Cobimetinib	BRAF	V600E
BTC0024	Amplification	2	Biliary Tract Cancer, NOS	Trastuzumab + Pertuzumab	ERBB2	strong amplification
BTC0033	Amplification	2	Biliary Tract Cancer, NOS	Trastuzumab + Pertuzumab	ERBB2	strong amplification
BTC0038	Amplification	2	Biliary Tract Cancer, NOS	Trastuzumab + Pertuzumab	ERBB2	FISH
BTC0024	Amplification	3.5	Colorectal Cancer	Lapatinib + Trastuzumab	ERBB2	strong amplification
BTC0033	Amplification	3.5	Colorectal Cancer	Lapatinib + Trastuzumab	ERBB2	strong amplification
BTC0038	Amplification	3.5	Colorectal Cancer	Lapatinib + Trastuzumab	ERBB2	FISH
BTC0024	Amplification	3.5	Colorectal Cancer	Trastuzumab + Pertuzumab	ERBB2	strong amplification
BTC0033	Amplification	3.5	Colorectal Cancer	Trastuzumab + Pertuzumab	ERBB2	strong amplification
BTC0038	Amplification	3.5	Colorectal Cancer	Trastuzumab + Pertuzumab	ERBB2	FISH
BTC0024	Amplification	3.5	Colorectal Cancer	Trastuzumab Deruxtecan	ERBB2	strong amplification
BTC0033	Amplification	3.5	Colorectal Cancer	Trastuzumab Deruxtecan	ERBB2	strong amplification
BTC0038	Amplification	3.5	Colorectal Cancer	Trastuzumab Deruxtecan	ERBB2	FISH
BTC0024	Amplification	3.5	Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma	Trastuzumab + Carboplatin-Taxol Regimen	ERBB2	strong amplification
BTC0033	Amplification	3.5	Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma	Trastuzumab + Carboplatin-Taxol Regimen	ERBB2	strong amplification
BTC0038	Amplification	3.5	Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma	Trastuzumab + Carboplatin-Taxol Regimen	ERBB2	FISH
BTC0019	G12D	3.5	Erdheim-Chester Disease	Cobimetinib, Trametinib	KRAS	G12D
BTC0019	G12D	3.5	Erdheim-Chester Disease	Cobimetinib, Trametinib	KRAS	G12D
BTC0077	G12R	3.5	Erdheim-Chester Disease	Cobimetinib, Trametinib	KRAS	G12R
BTC0077	G12R	3.5	Erdheim-Chester Disease	Cobimetinib, Trametinib	KRAS	G12R
BTC0019	G12D	3.5	Langerhans Cell Histiocytosis	Cobimetinib, Trametinib	KRAS	G12D
BTC0019	G12D	3.5	Langerhans Cell Histiocytosis	Cobimetinib, Trametinib	KRAS	G12D
BTC0077	G12R	3.5	Langerhans Cell Histiocytosis	Cobimetinib, Trametinib	KRAS	G12R
BTC0077	G12R	3.5	Langerhans Cell Histiocytosis	Cobimetinib, Trametinib	KRAS	G12R
BTC0019	G12D	3.5	Rosai-Dorfman Disease	Cobimetinib, Trametinib	KRAS	G12D
BTC0019	G12D	3.5	Rosai-Dorfman Disease	Cobimetinib, Trametinib	KRAS	G12D
BTC0077	G12R	3.5	Rosai-Dorfman Disease	Cobimetinib, Trametinib	KRAS	G12R
BTC0077	G12R	3.5	Rosai-Dorfman Disease	Cobimetinib, Trametinib	KRAS	G12R
BTC0011	Amplification	3.5	Non-Small Cell Lung Cancer	Capmatinib	MET	strong amplification
BTC0024	Amplification	3.5	Non-Small Cell Lung Cancer	Capmatinib	MET	strong amplification
BTC0011	Amplification	3.5	Non-Small Cell Lung Cancer	Crizotinib	MET	strong amplification
BTC0024	Amplification	3.5	Non-Small Cell Lung Cancer	Crizotinib	MET	strong amplification
BTC0011	Amplification	3.5	Non-Small Cell Lung Cancer	Tepotinib	MET	strong amplification
BTC0024	Amplification	3.5	Non-Small Cell Lung Cancer	Tepotinib	MET	strong amplification
BTC0064	E542K	3.5	Breast Cancer	Alpelisib + Fulvestrant	PIK3CA	E542K
BTC0027	E545K	3.5	Breast Cancer	Alpelisib + Fulvestrant	PIK3CA	E545K
BTC0015	V600	3.5	Histiocytosis	Vemurafenib, Dabrafenib	BRAF	V600E
BTC0020	Amplification	3.5	Esophagogastric Cancer	Cetuximab, Cetuximab + Chemotherapy, Panitumumab, Panitumumab + Chemotherapy	EGFR	strong amplification
BTC0010	Fusions	3	Cholangiocarcinoma	RLY-4008	FGFR2	FGFR2
BTC0018	Fusions	3	Cholangiocarcinoma	RLY-4008	FGFR2	FGFR2
BTC0026	Fusions	3	Cholangiocarcinoma	RLY-4008	FGFR2	FGFR2
BTC0070	Fusions	3	Cholangiocarcinoma	RLY-4008	FGFR2	FGFR2
BTC0018	R132	3.5	Glioma (excluding Oligodendroglioma)	Ivosidenib	IDH1	R132H
BTC0018	R132	3.5	Glioma (excluding Oligodendroglioma)	Ivosidenib	IDH1	R132H
BTC0018	R132	3.5	Glioma (excluding Oligodendroglioma)	Ivosidenib	IDH1	R132H
BTC0028	R132	3.5	Glioma (excluding Oligodendroglioma)	Ivosidenib	IDH1	R132C
BTC0028	R132	3.5	Glioma (excluding Oligodendroglioma)	Ivosidenib	IDH1	R132C
BTC0028	R132	3.5	Glioma (excluding Oligodendroglioma)	Ivosidenib	IDH1	R132C
BTC0028	R132	3.5	Glioma (excluding Oligodendroglioma)	Ivosidenib	IDH1	R132C
BTC0028	R132	3.5	Glioma (excluding Oligodendroglioma)	Ivosidenib	IDH1	R132C
BTC0028	R132	3.5	Glioma (excluding Oligodendroglioma)	Ivosidenib	IDH1	R132C
BTC0042	R132	3.5	Glioma (excluding Oligodendroglioma)	Ivosidenib	IDH1	R132C
BTC0042	R132	3.5	Glioma (excluding Oligodendroglioma)	Ivosidenib	IDH1	R132C
BTC0042	R132	3.5	Glioma (excluding Oligodendroglioma)	Ivosidenib	IDH1	R132C
BTC0054	R132	3.5	Glioma (excluding Oligodendroglioma)	Ivosidenib	IDH1	R132C
BTC0054	R132	3.5	Glioma (excluding Oligodendroglioma)	Ivosidenib	IDH1	R132C
BTC0054	R132	3.5	Glioma (excluding Oligodendroglioma)	Ivosidenib	IDH1	R132C
BTC0064	R132	3.5	Glioma (excluding Oligodendroglioma)	Ivosidenib	IDH1	R132H
BTC0064	R132	3.5	Glioma (excluding Oligodendroglioma)	Ivosidenib	IDH1	R132H
BTC0064	R132	3.5	Glioma (excluding Oligodendroglioma)	Ivosidenib	IDH1	R132H
BTC0018	R132	3.5	Oligodendroglioma, Astrocytoma	Vorasidenib	IDH1	R132H
BTC0018	R132	3.5	Oligodendroglioma, Astrocytoma	Vorasidenib	IDH1	R132H
BTC0018	R132	3.5	Oligodendroglioma, Astrocytoma	Vorasidenib	IDH1	R132H
BTC0028	R132	3.5	Oligodendroglioma, Astrocytoma	Vorasidenib	IDH1	R132C
BTC0028	R132	3.5	Oligodendroglioma, Astrocytoma	Vorasidenib	IDH1	R132C
BTC0028	R132	3.5	Oligodendroglioma, Astrocytoma	Vorasidenib	IDH1	R132C
BTC0028	R132	3.5	Oligodendroglioma, Astrocytoma	Vorasidenib	IDH1	R132C
BTC0028	R132	3.5	Oligodendroglioma, Astrocytoma	Vorasidenib	IDH1	R132C
BTC0028	R132	3.5	Oligodendroglioma, Astrocytoma	Vorasidenib	IDH1	R132C
BTC0042	R132	3.5	Oligodendroglioma, Astrocytoma	Vorasidenib	IDH1	R132C
BTC0042	R132	3.5	Oligodendroglioma, Astrocytoma	Vorasidenib	IDH1	R132C
BTC0042	R132	3.5	Oligodendroglioma, Astrocytoma	Vorasidenib	IDH1	R132C
BTC0054	R132	3.5	Oligodendroglioma, Astrocytoma	Vorasidenib	IDH1	R132C
BTC0054	R132	3.5	Oligodendroglioma, Astrocytoma	Vorasidenib	IDH1	R132C
BTC0054	R132	3.5	Oligodendroglioma, Astrocytoma	Vorasidenib	IDH1	R132C
BTC0064	R132	3.5	Oligodendroglioma, Astrocytoma	Vorasidenib	IDH1	R132H
BTC0064	R132	3.5	Oligodendroglioma, Astrocytoma	Vorasidenib	IDH1	R132H
BTC0064	R132	3.5	Oligodendroglioma, Astrocytoma	Vorasidenib	IDH1	R132H
BTC0019	G12D	3.5	Non-Small Cell Lung Cancer	RMC-6236	KRAS	G12D
BTC0019	G12D	3.5	Non-Small Cell Lung Cancer	RMC-6236	KRAS	G12D
BTC0077	G12R	3.5	Non-Small Cell Lung Cancer	RMC-6236	KRAS	G12R
BTC0077	G12R	3.5	Non-Small Cell Lung Cancer	RMC-6236	KRAS	G12R
BTC0019	G12D	3.5	Pancreatic Adenocarcinoma	RMC-6236	KRAS	G12D
BTC0019	G12D	3.5	Pancreatic Adenocarcinoma	RMC-6236	KRAS	G12D
BTC0077	G12R	3.5	Pancreatic Adenocarcinoma	RMC-6236	KRAS	G12R
BTC0077	G12R	3.5	Pancreatic Adenocarcinoma	RMC-6236	KRAS	G12R
BTC0019	G12D	3.5	Histiocytosis	Cobimetinib, Trametinib	KRAS	G12D
BTC0019	G12D	3.5	Histiocytosis	Cobimetinib, Trametinib	KRAS	G12D
BTC0077	G12R	3.5	Histiocytosis	Cobimetinib, Trametinib	KRAS	G12R
BTC0077	G12R	3.5	Histiocytosis	Cobimetinib, Trametinib	KRAS	G12R
BTC0014	Amplification	3.5	Dedifferentiated Liposarcoma	Brigimadlin	MDM2	strong amplification
BTC0034	Amplification	3.5	Dedifferentiated Liposarcoma	Brigimadlin	MDM2	strong amplification
BTC0034	Amplification	3.5	Dedifferentiated Liposarcoma	Brigimadlin	MDM2	strong amplification
BTC0039	Amplification	3.5	Dedifferentiated Liposarcoma	Brigimadlin	MDM2	strong amplification
BTC0057	Amplification	3.5	Dedifferentiated Liposarcoma	Brigimadlin	MDM2	strong amplification
BTC0078	Amplification	3.5	Dedifferentiated Liposarcoma	Brigimadlin	MDM2	strong amplification
BTC0014	Amplification	3.5	Intimal Sarcoma	Milademetan	MDM2	strong amplification
BTC0034	Amplification	3.5	Intimal Sarcoma	Milademetan	MDM2	strong amplification
BTC0034	Amplification	3.5	Intimal Sarcoma	Milademetan	MDM2	strong amplification
BTC0039	Amplification	3.5	Intimal Sarcoma	Milademetan	MDM2	strong amplification
BTC0057	Amplification	3.5	Intimal Sarcoma	Milademetan	MDM2	strong amplification
BTC0078	Amplification	3.5	Intimal Sarcoma	Milademetan	MDM2	strong amplification
BTC0014	Amplification	3.5	Well-Differentiated Liposarcoma	Brigimadlin	MDM2	strong amplification
BTC0034	Amplification	3.5	Well-Differentiated Liposarcoma	Brigimadlin	MDM2	strong amplification
BTC0034	Amplification	3.5	Well-Differentiated Liposarcoma	Brigimadlin	MDM2	strong amplification
BTC0039	Amplification	3.5	Well-Differentiated Liposarcoma	Brigimadlin	MDM2	strong amplification
BTC0057	Amplification	3.5	Well-Differentiated Liposarcoma	Brigimadlin	MDM2	strong amplification
BTC0078	Amplification	3.5	Well-Differentiated Liposarcoma	Brigimadlin	MDM2	strong amplification
BTC0011	Amplification	3.5	Non-Small Cell Lung Cancer	Telisotuzumab Vedotin	MET	strong amplification
BTC0024	Amplification	3.5	Non-Small Cell Lung Cancer	Telisotuzumab Vedotin	MET	strong amplification
